Multicenter Study to Compare Outcomes of Brain Tumor Resection Surgery Accompanied by GammaTile Therapy to Surgery Followed by Stereotactic Radiotherapy
Mindera dermal biomarker patch technology generates clinically validated data to lower healthcare costs and improve patient outcomes.
This is the first time that a large-scale, phase 3 randomized controlled trial in ophthalmology was able to be replicated using a real-world data set.
“We really don’t have a good diagnostic test for bowel function and motility. Using a little patch externally and noninvasively is an exciting concept.”
Partnership allows Ambra Health and Arterys platforms to directly integrate for improved interoperability.
Cannon Quality Group continues to serve the institute as an Enterprise Partner.
With this round, the company will be able to grow their partner and customer base, increasing enrollment rates and clinical outcomes across the country.
The company will use the funding to continue development of its Coral system, an innovative interventional robotics platform powered by microfluidics and an augmented reality digital user interface.
Moffitt is the first cancer center and the first hospital in Florida to use this new technology.
“It’s important to surround yourself with people who have the skills and expertise that you don’t have, which allows you to build a robust team.”